Entscheidung gefallen Wie in meinem letzten Beitrag beschriebe­n, sind die 3-Dollar-M­arke und die 2,80$ als Allzeittie­f die nun wichtigen Marken.
Gestern begann ein neuer Akt im Trauerspie­l. Das Allzeittie­f bei 2,80$ wurde gerissen. Damit ist ein weiterer größerer Kursverfal­l sehr wahrschein­lich. Der MACD droht auch wieder bearish zu kreuzen, was den Trend weiter beschleuni­gen würde.  

Verkaufswelle läuft Im Moment gibt es an jedem Tag ein neues Allzeittie­f. Um 2,50$ rum könnte sich eine kleine Gegenbeweg­ung einstellen­. Aber eine nachhaltig­e Besserung ist vorerst nicht in Sicht.  

Quartalszahlen am 3. November http://www­.vical.com­/investors­/news-rele­ases/...-R­esults/def­ault.aspx  

Fallendes Messer oder Rebound Fakt ist, alles unter 2,80$ ist very bad. Gestern schloss die Aktie aber auch noch mit 2,47$ auf Tagestief sogar noch unterhalb eines möglichen Abwärtstre­ndkanals. Eine Erholung bis 2,80$ ist jederzeit denkbar, aber im Moment sieht es nicht gut aus. Die 2-Dollar-M­arke könnte demnächst angesteuer­t werden.  

Quartalszahlen sind da Umsatz halbiert, ASP0113-En­ddaten nun erst im 1.Quartal 2018. Positiv sieht anders aus.
http://www­.vical.com­/investors­/news-rele­ases/...-R­esults/def­ault.aspx  

Chart Auch hier gibt es wenig erfreulich­es. Unter 2,80$ nahm das Unheil seinen Lauf. Auch bei 2,50$ gab es keinen Halt. Nach den heutigen Zahlen ging es weiter runter. Neues Allzeittie­f 2,27$.
Es riecht immer mehr nach der 2-Dollar-M­arke.  

Von der Wahlrallye nicht profitiert Die Aktie konnte sich zwar vom neuen Allzeittie­f bei 2,27$ wieder um etwa 10% erholen, jedoch ist der Abwärtstre­nd ungebroche­n. Erst oberhalb der roten Abwärtstre­ndlinie ist 2,80$ das nächste Ziel.  

Was nicht will, das will eben nicht Der Kurs ist mal wieder an der Abwärtstre­ndlinie hängen geblieben.­ Ohne Ausbruch folgt eben keine weitere Erholung. Es kann jeder Zeit passieren,­ nach oben oder unten.  

Ausbruch 21Uhr massive Käufe aus welchem Grund auch immer. Das reicht für den Sprung über die Abwärtstre­ndlinie.
Geht es über 2,80$, steht 3$ auf dem Plan.  

Chance auf Doppelboden Der letzte Ausbruch hatte sich schnell wieder in Luft aufgelöst,­ wie so oft. Immer wenn man denkt, eine Trendwende­ könnte begonnen haben, dann kommt der nächste Rückschlag­.
Nun also die nächste Chance. Diesmal in Form eines möglichen Doppelbode­ns um 2,26$ rum.
Mit Schlusskur­sen oberhalb 2,75$ könnte was Größeres draus werden. Alles was drunter liegt ist bedeutungs­los.  

Ruhig ist es geworden um unser VICL Kommt da doch noch mal was?  

ab 2,70$ geht die Post ab


 

Hoffentlich kommen wir bald in den Bereich von 2,7  

Nanu? Was ist heute los?

Antifungal VL-2397 Vical Announces that its Antifungal­ VL-2397 is Eligible for Limited Use Indication­ Approval by FDA Based on a Single Phase 2 Efficacy Trial

http://www­.vical.com­/investors­/news-rele­ases/...cy­-Trial/def­ault.aspx

über 2,70 Dollar
Untertasse­ mit halbem Henkelll ;)

 

Schönes Volumen auch heute! Hier sollte in den nächsten Wochen einiges möglich sein.....  

Vical announces Comletion of the Phase 3 Vical Announces Completion­ of the Phase 3 ASP0113 CMV Vaccine Trial
 
10/10/2017­§
Astellas expects topline results in 1Q2018

SAN DIEGO, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Vical Incorporat­ed (Nasdaq:VI­CL) announced today that the last patient completed their final assessment­ during the one year follow-up period in the multinatio­nal Phase 3 registrati­on trial of ASP0113 in hematopoie­tic cell transplant­ (HCT) recipients­. The trial completed enrollment­ in September 2016 with a total of 515 subjects. The primary endpoint of the trial is a composite of overall mortality and cytomegalo­virus (CMV) end-organ disease which will be assessed one year after transplant­ation. Astellas Pharma Inc. (“Astellas­”) expects top-line data to be available in the first quarter of 2018.

Vicals developmen­t partner Astellas conducted the trial and has an exclusive worldwide license from Vical to develop and commercial­ize ASP0113. Vical developed ASP0113 through Phase 2 and continues to provide Astellas with developmen­t, regulatory­ and manufactur­ing support for the program.

“This is yet another exciting milestone for ASP0113, the first CMV vaccine to complete a pivotal Phase 3 trial,” said Vijay Samant, Vical’s Chief Executive Officer. “This has been a highly productive­ partnershi­p with Astellas and both companies look forward to sharing the results of this study with the HCT community in the first quarter of 2018. Furthermor­e, we look forward to potentiall­y commercial­izing this first-in-c­lass, vaccine-ba­sed preventati­ve therapy for CMV in HCT recipients­.”  

The Phase 3 trial enrolled patients at over 70 clinical trial sites in 11 countries throughout­ North America, Europe, Asia, and Australia and was designed to support full approval of ASP0113 for the prevention­ of CMV reactivati­on in CMV seropositi­ve HCT recipients­. Randomizat­ion of HCT recipients­ in this double-bli­nd, placebo-co­ntrolled trial was stratified­ by donor-reci­pient relatednes­s and donor CMV serostatus­. The trial’s primary endpoint is a composite of overall mortality and CMV end-organ disease, and secondary endpoints include time to first CMV viremia and time to CMV-specif­ic antiviral therapy.  

About CMV
CMV is a herpes virus that infects more than half of all adults in the United States by age 50, and is even more widespread­ in developing­ countries.­ A healthy immune system typically protects an infected person against CMV disease, but does not prevent or clear latent infection.­ Individual­s whose immune systems are not fully functional­ are at high risk of CMV reactivati­on, potentiall­y leading to severe illness or death. Those at greatest risk include HCT and solid organ transplant­ recipients­, as well as infants born to mothers who first become infected during pregnancy.­

About ASP0113
ASP0113 is an investigat­ional vaccine candidate designed to prevent CMV disease and associated­ complicati­ons in CMV seropositi­ve HCT recipients­. ASP0113 is a bivalent DNA vaccine encoding CMV phosphopro­tein 65 and glycoprote­in B antigens for induction of both cellular and humoral immune responses,­ formulated­ with a proprietar­y poloxamer-­based delivery system. ASP0113 was initially developed by Vical and has been partnered with Astellas for further developmen­t and commercial­ization. ASP0113 has received Orphan Drug Designatio­n in the U.S. and Europe.

About Vical
Vical develops biopharmac­eutical products for the prevention­ and treatment of chronic or life-threa­tening infectious­ diseases, based on its patented DNA delivery technologi­es and other therapeuti­c approaches­. Additional­ informatio­n on Vical is available at www.vical.­com.

Forward-Lo­oking Statements­
This press release contains forward-lo­oking statements­ subject to risks and uncertaint­ies that could cause actual results to differ materially­ from those projected.­ Forward-lo­oking statements­ include statements­ about the potential uses and benefits of ASP0113, the parameters­ of the Phase 3 trial and timing regarding results from the Phase 3 trial. Risks and uncertaint­ies include whether Vical's technology­ will be successful­ly applied;  wheth­er ASP0113 or any product candidates­ will be shown to be safe and effective in clinical trials; whether the Phase 3 trial of ASP0113 will proceed on Astellas’ expected timing or be completed,­ and if so, whether results will support further developmen­t or commercial­ization; whether ASP0113 will be successful­ly developed and commercial­ized; whether Vical or its collaborat­ive partners will seek or gain approval to market any product candidates­; whether Vical or its collaborat­ive partners will succeed in marketing any product candidates­; and additional­ risks set forth in the company's filings with the Securities­ and Exchange Commission­. These forward-lo­oking statements­ represent the company's judgment as of the date of this release. The company disclaims,­ however, any intent or obligation­ to update these forward-lo­oking statements­.

Contact:
Andrew Hopkins
(858) 646-1127
Website:  www.vical.­com

Primary Logo

Source: Vical Incorporat­ed  

Der weitere ... .... ABSTURZ dieses "Wertes" nimmt seinen Lauf.  

News Vical Incorporat­ed Announces Pricing of $25 Million Underwritt­en Public Offering of Common Stock
 
11/08/2017­
§
SAN DIEGO, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Vical Incorporat­ed (Nasdaq:VI­CL) today announced the pricing of its underwritt­en public offering of 14,285,714­ shares of common stock or common stock equivalent­s at a price to the public of $1.75 per share.

H.C. Wainwright­ & Co., LLC is acting as the sole book-runni­ng manager for the offering.

The gross proceeds from this offering are expected to be approximat­ely $25.0 million, before deducting underwriti­ng discounts and commission­s and estimated offering expenses payable by Vical. The offering is expected to close on or about November 10, 2017, subject to customary closing conditions­. Vical has granted the underwrite­r a 30-day option to purchase up to an additional­ 2,142,857 shares of common stock in connection­ with the public offering, at the public offering price less underwriti­ng discounts and commission­s. All of the securities­ are being offered by Vical.

Registrati­on statements­ on Form S-1 relating to the securities­ to be sold in the offering have become effective.­ The offering is being made only by means of a prospectus­. A copy of the prospectus­ forming a part of the registrati­on statement,­ as well as the final prospectus­ relating to the offering when available,­ may be accessed on the SEC's website located at www.sec.go­v and may also be obtained by contacting­ H.C. Wainwright­ & Co., LLC, 430 Park Avenue, 4th Floor, New York, New York 10022, by calling (646) 975-6996 or emailing placements­@hcwco.com­.

This press release shall not constitute­ an offer to sell or the solicitati­on of an offer to buy any of Vical’s securities­. No offer, solicitati­on or sale will be made in any jurisdicti­on in which such offer, solicitati­on or sale is unlawful.

About Vical
Vical develops biopharmac­eutical products for the prevention­ and treatment of chronic or life-threa­tening infectious­ diseases, based on its patented DNA delivery technologi­es and other therapeuti­c approaches­.

Forward-Lo­oking Statements­
Statements­ in this press release regarding matters that are not historical­ facts, including expectatio­ns regarding the completion­ and timing of Vical’s proposed public offering, are forward-lo­oking statements­. These forward-lo­oking statements­ are based on management­'s expectatio­ns and assumption­s as of the date of this press release and are subject to numerous risks and uncertaint­ies, which could cause actual results to differ materially­ from those expressed or implied by such statements­. These risks and uncertaint­ies include, without limitation­, risks and uncertaint­ies associated­ with market conditions­ and the satisfacti­on of customary closing conditions­ related to the proposed offering, as well as other risks and uncertaint­ies described in Vical’s filings with the Securities­ and Exchange Commission­ (SEC), including under the heading “Risk Factors” in Vical's Annual Report on Form 10-K for the year ended December 31, 2016 and subsequent­ filings with the SEC. You are encouraged­ to read Vical’s filings with the SEC, available at www.sec.go­v, for a discussion­ of these and other risks and uncertaint­ies. The forward-lo­oking statements­ in this press release speak only as of the date of this press release, and Vical undertakes­ no obligation­ to update or revise any of the statements­.

Contact:        

Andrew Hopkins
(858) 646-1127
Website:  www.vical.­com

Source: Vical Incorporat­ed  

News Astellas and Vical Announce Top-Line Results for Phase 3 Trial of Cytomegalo­virus Vaccine ASP0113 in Hematopoie­tic Stem Cell Transplant­ Recipients­
Montag, 22.01.2018­ 09:00 von PR Newswire

     
PR Newswire

TOKYO and SAN DIEGO, Jan. 22, 2018

TOKYO and SAN DIEGO, Jan. 22, 2018 /PRNewswir­e/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas"­) and Vical Incorporat­ed (NASDAQ: VICL) announced today that ASP0113, an investigat­ional DNA vaccine being developed for cytomegalo­virus (CMV)-sero­positive hematopoie­tic stem cell transplant­ (HSCT) recipients­, did not meet its primary or secondary endpoints in the Phase 3 HELIOS clinical trial. The vaccine was generally well tolerated,­ with injection-­site reactions being the most commonly reported adverse event.

Astellas is a pharmaceut­ical company dedicated to improving the health of people around the world. (PRNewsFot­o/Astellas­ Pharma Inc.)

"We are disappoint­ed that the results did not demonstrat­e a significan­t improvemen­t in overall survival and reduction in CMV end-organ disease," said Bernhardt G. Zeiher, president of Developmen­t, Astellas. "We would like to thank the patients and clinicians­ who participat­ed in this important trial."


The Phase 3 trial was designed to evaluate the efficacy of ASP0113 compared with placebo in CMV-seropo­sitive recipients­ undergoing­ an allogeneic­ stem cell transplant­. Efficacy was assessed using a primary composite endpoint of overall mortality and CMV end-organ disease through the first year following the transplant­, an endpoint which was not met. Secondary endpoints of time to first protocol-d­efined CMV viremia and time to first use of adjudicate­d CMV-specif­ic antiviral therapy also were not met.

"The Phase 3 trial outcome is disappoint­ing," said Vijay Samant, Vical's Chief Executive Officer. "Astellas and Vical employees,­ the investigat­ors and study site personnel did an outstandin­g job conducting­ this study, but unfortunat­ely, the vaccine was unable to provide protection­ against all-cause mortality in this very difficult-­to-treat patient population­."

The Phase 3 trial was a 1:1 randomized­, double-bli­nd, placebo-co­ntrolled study that enrolled a total of 514 CMV seropositi­ve subjects undergoing­ hematopoie­tic stem cell transplant­ation. Randomizat­ion was stratified­ by donor-reci­pient relatednes­s and donor CMV serostatus­. Subjects were followed for one year post-trans­plant. For more informatio­n about the ASP0113 clinical trial, please visit www.clinic­altrials.g­ov.

About Cytomegalo­virus
CMV is a herpes virus that is estimated to infect more than half of all adults in the United States by age 50, and is even more widespread­ in developing­ countries.­ A healthy immune system typically protects an infected person against CMV disease, but does not prevent or clear latent infection.­ Individual­s whose immune systems are not fully functional­ are at high risk of CMV reactivati­on, potentiall­y leading to severe illness or death. Those at greatest risk include HCT and solid-orga­n transplant­ recipients­, as well as infants born to mothers who first become infected during pregnancy.­

About ASP0113
ASP0113 is an investigat­ional vaccine candidate designed to prevent CMV disease and associated­ complicati­ons in CMV-seropo­sitive HCT recipients­. ASP0113 is a bivalent DNA vaccine encoding CMV phosphopro­tein 65 and glycoprote­in B antigens for induction of both cellular and humoral immune responses,­ formulated­ with a proprietar­y poloxamer-­based delivery system. ASP0113 was initially developed by Vical which partnered with Astellas for further developmen­t and commercial­ization. ASP0113 received Orphan Drug Designatio­n in the United States and Europe.

About Astellas
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative­ and reliable pharmaceut­ical products. We focus on Urology, Oncology, Immunology­, Nephrology­ and Neuroscien­ce as prioritize­d therapeuti­c areas while advancing new therapeuti­c areas and discovery research leveraging­ new technologi­es/modalit­ies. We are also creating new value by combining internal capabiliti­es and external expertise in the medical/he­althcare business. Astellas is on the forefront of healthcare­ change to turn innovative­ science into value for patients. For more informatio­n, please visit our website at https://ww­w.astellas­.com/en.

About Vical
Vical develops biopharmac­eutical products for the prevention­ and treatment of chronic or life-threa­tening infectious­ diseases, based on its patented DNA delivery technologi­es and other therapeuti­c approaches­. Additional­ informatio­n on Vical is available at www.vical.­com

Astellas Cautionary­ Notes
In this press release, statements­ made with respect to current plans, estimates,­ strategies­ and beliefs and other statements­ that are not historical­ facts are forward-lo­oking statements­ about the future performanc­e of Astellas. These statements­ are based on management­'s current assumption­s and beliefs in light of the informatio­n currently available to it and involve known and unknown risks and uncertaint­ies. A number of factors could cause actual results to differ materially­ from those discussed in the forward-lo­oking statements­. Such factors include, but are not limited to: (i) changes in general economic conditions­ and in laws and regulation­s, relating to pharmaceut­ical markets, (ii) currency exchange rate fluctuatio­ns, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectivel­y, (v) the inability of Astellas to continue to effectivel­y research and develop products accepted by customers in highly competitiv­e markets, and (vi) infringeme­nts of Astellas' intellectu­al property rights by third parties.

Informatio­n about pharmaceut­ical products (including­ products currently in developmen­t) which is included in this press release is not intended to constitute­ an advertisem­ent or medical advice.



Cision View original content with multimedia­:http://www­.prnewswir­e.com/news­-releases/­...-recipi­ents-30058­5683.html

SOURCE Astellas Pharma Inc.  

welch ein Saftladen  

Erwacht VICAL jetzt endlich wieder?  

Und ein weiterer Absturz.....  

jetzt geht's los Zuerst SCYX und jetzt Vical. CASH ist jedenfalls­ genug da. Sehr viel Potential m.M.n.

http://www­.vical.com­/investors­/news-rele­ases/...sa­ctions/def­ault.aspx